Skip to main content
Top
Published in: Intensive Care Medicine 5/2004

01-05-2004 | Correspondence

Ventilator-associated pneumonia: caveats for benchmarking

Authors: J. E. Tulleken, J. G. Zijlstra, J. J. M. Ligtenberg, R. Spanjersberg, T. S. van der Werf

Published in: Intensive Care Medicine | Issue 5/2004

Login to get access

Excerpt

Sir: We read with interest the article by Eggimann et al. [1]. Their results contribute to the growing understanding of the risk of biased risk assessment and jeopardized benchmarking between units. Results of our own unit support and add to this theory. We evaluated the incidence of ventilator associated pneumonia (VAP), definitions were based on the recommendations by the Centers for Disease Control, and the adherence of the staff to local prevention protocols in our 12-bed ICU during a 3 month follow up on a yearly basis. The ICU has a predominantly medical patient population, a substantial number of immune-compromised patients, and a large caseload of critically ill patients transferred from other hospitals. We identified one definite and one probable VAP/1000 ventilator days (Table 1).
Table 1
Patient characteristics and reasons for admission during a 3-month observation period
Characteristic
Year
1999
2000
2001
2002
Patients (n)
140
140
138
132
Female (n)
56
65
65
55
Age, years (mean, range)
56 (18–92)
58 (17–94)
56 (14–81)
57 (17–88)
ICU days
7.4 (1–62)
6.8 (1–79)
5.7 (1–53)
6.6 (1–44)
Ventilated patients (n)
87
81
82
76
Ventilated ≥3 days (n)
65
52
49
50
Ventilator days (median)
8 (3–62)
7 (3–79)
5 (3–26)
6 (3–35)
Ventilator days (total)
653
583
387
429
VAP definite (n pts)
0
1
0
1
VAP probable (n pts)
0
1
0
1
Medical
103 (74%)
88 (63%)
96 (70%)
85 (64%)
Intoxication
7 (5%)
8 (6%)
6 (4%)
9 (7%)
Scheduled surgery
21 (15%)
28 (20%)
26 (19)
23 (17%)
Emergency surgery
5 (4%)
10 (7%)
3 (2%)
7 (5%)
Trauma
3 (2%)
5 (4%)
3 (2%)
5 (4%)
Neurological
1 (1%)
1 (1%)
3 (2%)
4 (3%)
Literature
1.
go back to reference Eggimann P, Hugonnet S, Sax H, Touveneau S, Chevrolet JC, Pittet D (2003) Ventilator-associated pneumonia: caveats for benchmarking. Intensive Care Med 29:2086–2089CrossRefPubMed Eggimann P, Hugonnet S, Sax H, Touveneau S, Chevrolet JC, Pittet D (2003) Ventilator-associated pneumonia: caveats for benchmarking. Intensive Care Med 29:2086–2089CrossRefPubMed
2.
go back to reference Parienti JJ, Ramakers M, Charbonneau P (2001) Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med 164:172–173PubMed Parienti JJ, Ramakers M, Charbonneau P (2001) Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med 164:172–173PubMed
3.
go back to reference Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J (1999) Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 160:608–613PubMed Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J (1999) Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 160:608–613PubMed
Metadata
Title
Ventilator-associated pneumonia: caveats for benchmarking
Authors
J. E. Tulleken
J. G. Zijlstra
J. J. M. Ligtenberg
R. Spanjersberg
T. S. van der Werf
Publication date
01-05-2004
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 5/2004
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-004-2247-z

Other articles of this Issue 5/2004

Intensive Care Medicine 5/2004 Go to the issue